Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Pennsylvania
Clinical trial register · United States · industry-sponsored

Clinical Trials in Pennsylvania, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9118 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 06 Oct 2026, 03:16 UTC
9118
Studies in scope
industry-sponsored, all four open statuses
4945
Recruiting now
open to new participants
2189
Lead sponsors
across recruiting studies
Top states
California 109 Florida 91 Colorado 71 Georgia 67 Illinois 56
Narrow the registerReset
Recruitment status
Phase
Target enrolment
to

Trials with a site in Pennsylvania

17 of 9118 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Active, closed
A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis
NCT07230860Dermatitis, Atopic
Janssen Research & Development, LLC
Phase 2
189
California, Florida, Illinois, Indiana, Michigan, North Dakota, Oregon, Pennsylvania
2026-01-20
Active, closed
A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis
NCT06878404Arthritis, Psoriatic
Janssen Research & Development, LLC
Phase 3
552
Arkansas, Florida, Illinois, North Carolina, Pennsylvania, Texas
2025-02-21
Active, closed
A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma
NCT06550895Multiple Myeloma
Janssen Research & Development, LLC
Phase 2
11
Iowa, Kentucky, Michigan, New York, Pennsylvania
2024-09-16
Active, closed
A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)
NCT05784441Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
Janssen Research & Development, LLC
Phase 1
21
Iowa, Kentucky, Minnesota, New Jersey, Ohio, Pennsylvania, Texas
2023-11-06
Recruiting
A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
NCT06095089Prostatic Neoplasms
Janssen Research & Development, LLC
Phase 1
355
Colorado, Georgia, Minnesota, New Jersey, New York, North Carolina, Oregon, Pennsylvania
2023-11-01
Recruiting
A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
NCT05818683Metastatic Castration-resistant Prostate Neoplasms, Metastatic Hormone-sensitive Prostate Cancer
Janssen Research & Development, LLC
Phase 1
300
Florida, Michigan, Missouri, New York, Pennsylvania
2023-04-26
Recruiting
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
NCT05652335Relapsed or Refractory Multiple Myeloma, Previously Treated Amyloid Light-chain (AL) Amyloidosis
Janssen Research & Development, LLC
Phase 1
180
California, Colorado, New York, North Carolina, Pennsylvania, Texas
2022-11-22
Active, closed
A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
NCT05421663Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse
Janssen Research & Development, LLC
Phase 1/2
166
California, Colorado, Iowa, Kentucky, New Jersey, North Carolina, Ohio, Pennsylvania
2022-08-12
Recruiting
A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis
NCT05265273Myasthenia Gravis
Janssen Research & Development, LLC
Phase 2/3
12
Arizona, California, Colorado, Florida, Kansas, Michigan, Pennsylvania
2022-07-20
Active, closed
A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT04557098Hematological Malignancies
Janssen Research & Development, LLC
Phase 2
194
Alabama, California, Georgia, Michigan, New York, North Carolina, Pennsylvania
2020-09-17
Active, closed
A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma
NCT04108195Multiple Myeloma
Janssen Research & Development, LLC
Phase 1
290
California, New York, North Carolina, Pennsylvania, Tennessee, Wisconsin
2020-02-21
Active, closed
A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer
NCT04077463Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC
Phase 1
701
California, Florida, Massachusetts, Michigan, Missouri, New York, Oregon, Pennsylvania
2019-09-04
Active, closed
A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer
NCT03473743Urothelial Carcinoma
Janssen Research & Development, LLC
Phase 1/2
125
Colorado, Kentucky, Maryland, New Jersey, New York, North Carolina, Ohio, Pennsylvania
2018-04-05
Active, closed
A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer
NCT03431350Prostatic Neoplasms, Castration-Resistant
Janssen Research & Development, LLC
Phase 2
136
Arizona, Colorado, Florida, Indiana, Maryland, Michigan, New York, Pennsylvania
2018-03-02
Active, closed
Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma
NCT03145181Hematological Malignancies
Janssen Research & Development, LLC
Phase 1
302
California, Colorado, New York, North Carolina, Pennsylvania
2017-05-16
Active, closed
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers
NCT02908906Neoplasms
Janssen Research & Development, LLC
Phase 1/2
234
Missouri, Pennsylvania
2016-11-21
Rows per page Showing 1–17 of 17
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 6 October 2026. https://priyalifescience.com/clinical-trials-usa/state/pennsylvania

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,118 studies in total at the last sync on 06 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 17 of those studies with a site in Pennsylvania that also match the filters currently applied.

How many clinical trials are recruiting in Pennsylvania?

4 of the 17 studies on this page are recruiting new participants as of the 06 Oct 2026, 03:16 UTC sync. A further 0 have not yet opened recruitment, 13 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Pennsylvania), 17 studies
PhaseStudiesRecruitingShare
Phase 17341.2%
Phase 24023.5%
Phase 1/23017.6%
Phase 32011.8%
Phase 2/3115.9%

Most active sponsors

Lead sponsors with the most studies (Pennsylvania)
Lead sponsorStudiesRecruiting
Janssen Research & Development, LLC174
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.